Apoptotic Vesicles Derived from Mesenchymal Stem Cells Ameliorate Hypersensitivity Responses via Inducing CD8(+) T Cells Apoptosis with Calcium Overload and Mitochondrial Dysfunction.

间充质干细胞来源的凋亡小泡通过诱导 CD8(+) T 细胞凋亡、钙过载和线粒体功能障碍来改善超敏反应

阅读:5
作者:Liu Anqi, Peng Peng, Wei Changze, Meng Fanhui, Huang Xiaoyao, Liu Peisheng, Fan Siyuan, Cai Xinyue, Wu Meiling, Xuan Zilin, Liu Qing, Qiu Xinyu, Zhu Zhenlai, Guo Hao
Apoptosis is crucial for maintaining internal homeostasis. Apoptotic vesicles (ApoVs) derived from mesenchymal stem/ stromal cells (MSCs-ApoVs) as natural lipid nanoparticles are attractive candidates for the next generation of immunotherapies. However, the therapeutic potential of MSCs-ApoVs in managing hypersensitivity reactions mediated by CD8(+) T cells remains elusive. This research utilized contact hypersensitivity and oral lichenoid reaction models, both of which represent type IV hypersensitivity reactions. ApoVs are shown that derived from stem cells from human exfoliated deciduous teeth (SHED-ApoVs), a subtype of MSCs, directly fused with the plasma membrane of CD8(+) T cells, subsequently increasing membrane permeability through L-type voltage-gated Ca(2+) channels. This initiates a cascade of events including calcium overload, mitochondrial dysfunction, and the initiation of apoptosis in these cells. As known, this is the first study to characterize SHED-ApoVs as immune microenvironment modulators, demonstrating their therapeutic potential and mechanism in these reactions. Moreover, analysis of blood samples from patients with oral lichenoid reactions verified the antihypersensitivity property of SHED-ApoVs. This study sheds light on the therapeutic prospects of MSCs-ApoVs and their underlying mechanisms in diseases mediated by CD8(+) T cells, contributing novel perspectives for the clinical application of ApoVs and nanovesicle-based cell-free therapies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。